A detailed history of Commonwealth Equity Services, LLC transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Commonwealth Equity Services, LLC holds 483,351 shares of GALT stock, worth $1.31 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
483,351
Previous 115,741 317.61%
Holding current value
$1.31 Million
Previous $277,000 294.22%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
$2.13 - $4.2 $783,009 - $1.54 Million
367,610 Added 317.61%
483,351 $1.09 Million
Q1 2024

Apr 29, 2024

BUY
$1.6 - $2.44 $16,568 - $25,266
10,355 Added 9.83%
115,741 $277,000
Q4 2023

Feb 06, 2024

SELL
$1.6 - $2.18 $1,817 - $2,476
-1,136 Reduced 1.07%
105,386 $175,000
Q3 2023

Oct 23, 2023

BUY
$1.38 - $1.97 $6,899 - $9,850
5,000 Added 4.93%
106,522 $205,000
Q4 2022

Feb 07, 2023

BUY
$1.03 - $1.66 $65,201 - $105,081
63,302 Added 165.63%
101,522 $114,000
Q2 2022

Jul 19, 2022

BUY
$1.19 - $1.74 $13,468 - $19,693
11,318 Added 42.07%
38,220 $50,000
Q1 2022

May 04, 2022

BUY
$1.61 - $2.31 $16,100 - $23,100
10,000 Added 59.16%
26,902 $43,000
Q4 2021

Jan 31, 2022

BUY
$2.07 - $3.8 $10,350 - $19,000
5,000 Added 42.01%
16,902 $34,000
Q3 2021

Oct 29, 2021

BUY
$2.59 - $4.15 $30,826 - $49,393
11,902 New
11,902 $46,000
Q4 2019

Feb 05, 2020

SELL
$2.79 - $4.32 $45,622 - $70,640
-16,352 Closed
0 $0
Q3 2019

Oct 30, 2019

BUY
$3.0 - $4.05 $3,315 - $4,475
1,105 Added 7.25%
16,352 $60,000
Q2 2019

Jul 19, 2019

BUY
$3.61 - $5.0 $11,042 - $15,295
3,059 Added 25.1%
15,247 $63,000
Q1 2019

May 13, 2019

BUY
$3.86 - $6.02 $3,860 - $6,020
1,000 Added 8.94%
12,188 $62,000
Q4 2018

Feb 11, 2019

BUY
$3.43 - $5.74 $38,374 - $64,219
11,188 New
11,188 $38,000

Others Institutions Holding GALT

About GALECTIN THERAPEUTICS INC


  • Ticker GALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,426,000
  • Market Cap $160M
  • Description
  • Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...
More about GALT
Track This Portfolio

Track Commonwealth Equity Services, LLC Portfolio

Follow Commonwealth Equity Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.